US Patent

US11139056 — Methods of treating overweight and obesity

Method of Use · Assigned to Nalpropion Pharmaceuticals LLC · Expires 2033-06-05 · 7y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjec…

USPTO Abstract

The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1583`	—

Patent Metadata

Patent number: US11139056
Jurisdiction: US
Classification: Method of Use
Expires: 2033-06-05
Drug substance claim: No
Drug product claim: No
Assignee: Nalpropion Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.